Regeneron Provides Update on EYLEA HD (aflibercept) Injection 8 mg Supplemental Biologics License Application
TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:…
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody,…
Three-Year Results for EYLEA HD (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals
At three years of EYLEA HD treatment, the vast majority of patients…
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trialin Patients with Idiopathic Pulmonary Fibrosis
February 07, 2025 16:58 ET | Source: Pliant Therapeutics, Inc. Following DSMB…
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreichs Ataxia
January 23, 2025 16:05 ET | Source: Larimar Therapeutics Adolescents receive a…
Hedia and Glooko Partner to Elevate Diabetes Management with Personalised Bolus Insulin Dosing
New integration delivers personalised insulin dosing advice, improving care for people with diabetes…
Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
− Single Dose of Nucresiran 300mg or Higher Led to Rapid Knockdown…
